Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22
11.04.2023 - UCART22 is currently the most advanced allogeneic CAR T-cell product in development for relapsed or refractory B-cell acute lymphoblastic leukemia The BALLI-01 study (evaluating UCART22) is actively enrolling patients with relapsed or refractory ... Seite 1